PRNewswire: July 20, 2017 – PRINCETON, NJ, U.S.A., and LUND, Sweden – Braeburn Pharmaceuticals (“Braeburn”) and Camurus (NASDAQ STO: CAMX) today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the…
